Feng F, Gao Q, Wu Y, et al. - Researchers undertook this retrospective cohort study to compare prognosis in patients suffering from advanced intrahepatic cholangiocarcinoma (ICC) receiving cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone. They analyzed 51 and 61 patients in the CRS + HIPEC and CRS groups, respectively. Longer hospital stay was noted in the CRS + HIPEC group. The CRS + HIPEC group was found to have lower postoperative CA19-9 levels, relative to the CRS group. A longer median overall survival (OS) was observed in the CRS + HIPEC group vs in the CRS group. A higher occurrence of leukopenia but a lower occurrence of total bilirubin increase was identified in the CRS + HIPEC group vs the CRS group. Overall, CRS + HIPEC offered improved OS and similar complications and adverse events in comparison to CRS alone, and therefore, could represent a therapeutic choice for patients with advanced ICC.